NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

(Yicai) Jan. 14 -- WuXi AppTec’s shares rose after the pharmaceutical services provider sold stakes in an affiliated company, ...

The companies have committed to working in close collaboration to ensure a smooth transition for employees and customers.

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

WuXi AppTec, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...